Table 1.
the effect of melatonin administration in different experimental groups.
| Parameters | Group I | Group II | Group III | Group IV |
|---|---|---|---|---|
| Body weight (gm) | 220.12 ± 0.53 | 225.65 ± 2.41 | 145.50 ± 0.32a | 201.53 ± 0.54a,b |
| Insulin (ng/ml) | 3.01 ± 1.25 | 3.91 ± 0.47 | 0.91 ± 1.96 a | 2.8 ± 3.21b |
| FBG level (mg/dl) | 89.08 ± 0.65 | 80.11 ± 4.21 | 244.18 ± 1.23a | 91.93 ± 0.25b |
| FTA (µmol/L) | 157.51 ± 0.69 | 149.15 ± 1.01 | 298.83 ± 0.75 a | 168.54 ± 1.59a,b |
| Liver function | ||||
| ALT (U/L) | 25.07 ± 1.65 | 26.01 ± 2.01 | 45.56 ± 2.50a | 29.44 ± 0.65b |
| AST (U/L) | 21.69 ± 0.87 | 20.31 ± 1.54 | 35.55 ± 1.80a | 23.85 ± 0.43a |
| Kidney function | ||||
| Urea (mg/dl) | 37.64 ± 0.59 | 35.74 ± 5.40 | 83.53 ± 1.43a | 39.65 ± 1.92a,b |
| Creatinine (mg/dl) | 0.43 ± 2.57 | 0.44 ± 0.48 | 1.43 ± 2.46 a | 0.73 ± 1.75b |
In each raw, results were expressed as mean ± SD, arepresents significance compared with the corresponding healthy control group I and brepresents significance compared with the corresponding diabetic group III (P < 0.05). Group I: healthy control rats, group II: melatonin administrated control rats, group III: non-treated STZ diabetic rats and group IV: melatonin treated STZ diabetic rats